Papa John’s sinks nearly 20% on report Apollo withdrew its offer to take chain private

Papa John’s sinks nearly 20% on report Apollo withdrew its offer to take chain private


Shares of Papa John’s sank nearly 20% on Tuesday following a report that Apollo Global has withdrawn its offer to take the pizza chain private.

Reuters reported that the private equity firm backtracked on its bid, valued at $64 a share, about a week ago. The firm previously submitted an offer for Papa John’s alongside Irth Capital Management, according to Reuters.

Apollo and Papa John’s did not immediately respond to requests for comment.

Papa John’s is preparing to release its third-quarter earnings report on Thursday. The company’s stock is down nearly 30% in the last year.



Source

Walmart reports strong holiday growth, but earnings outlook falls short of estimates
Business

Walmart reports strong holiday growth, but earnings outlook falls short of estimates

Walmart said on Thursday that holiday-quarter sales rose nearly 6% and its quarterly earnings and revenue surpassed Wall Street’s expectations as gains in e-commerce, advertising and its third-party marketplace boosted its business. For the full current fiscal year, Walmart said it expects net sales to increase by 3.5% to 4.5% and adjusted earnings per share […]

Read More
Wayfair posts first annual sales gain since 2020, outperforms overall furniture market
Business

Wayfair posts first annual sales gain since 2020, outperforms overall furniture market

Wayfair store in Wilmette, Illinois. Courtesy: Wayfair Wayfair‘s annual sales grew last year for the first time since 2020 as the online furniture company continues to win over value-seeking consumers, the retailer announced Thursday.  In 2025, Wayfair revenue grew 5.1% to $12.5 billion. The gains follow a more than 1% year-over-year decline in 2024. The […]

Read More
FDA chief warns U.S. is losing ground to China in early drug development, calls for faster trial approvals
Business

FDA chief warns U.S. is losing ground to China in early drug development, calls for faster trial approvals

Food and Drug Administration Commissioner Marty Makary warned that the U.S. is falling behind China in early-stage drug development and called for reforms that could streamline the process for starting trials on new treatments.  In an interview with CNBC on Wednesday, Makary specifically pointed to three bottlenecks that he said cause the U.S. to fall […]

Read More